FRT vs QNRX · rev $1.28B vs $9.6M cap
FRT (FRT) versus Quoin Pharmaceuticals Ltd DRC (QNRX) — a side-by-side from cached financials, not a winner call.
FRT (FRT) common stock.
Quoin Pharmaceuticals Ltd DRC (QNRX) is a biotechnology company listed on NASDAQ.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
QNRX does not have a complete income-statement cache yet.
FRT currently screens at market cap $0. QNRX currently screens at market cap $9.6M.
Not investment advice. Open the FRT and QNRX stock pages for the full models.
Not investment advice.